• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• v.26 no.3
• /
• pp.143-148
• /
• 2015

The purpose of this review was to investigate the relationship between aerobic exercise and cognitive function as well as synthesize the effect of aerobic exercise intervention studies centered on psychiatric symptoms associated with general cognitive deficit. Prospective studies on aerobic exercise and improvement of cognitive function were reviewed and synthesized. In addition, this literature review provides significant positive results on the relationship between aerobic exercise and general cognitive deficit associated with psychiatric symptoms. Review of this literature suggests that there is a positive relationship between participation in aerobic exercise and cognitive function. In this text, there are at least three general pathways by which aerobic exercise may facilitate executive function in children : 1) cognitive demands inherent in engaging in physical activity, 2) cognitive demands inherent in cooperation of complex motor tasks, and 3) physiological changes resulting from aerobic exercise. Another main finding of this review is that physical activity has a stronger influence on cognitive deficit, including attention-deficit hyperactivity disorder, depression, and anxiety. Development of cognitive function is the most important factor for children and youth. Therefore, future research should prove relationship between physical activity and cognitive function using a more scientific and quantitative approach design.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.36 no.4
• /
• pp.61-77
• /
• 2023

Objectives: This study aimed to identify the current use and investigate the clinical practice of Korean Medicine for climacteric syndrome and postmenopausal syndrome outpatients. Methods: We studied climactic syndrome and postmenopausal syndrome outpatients who visited Daejeon Korean Medicine Hospital of Daejeon University from January 1, 2019 to December 31, 2021 via an analysis of the medical records. Results: 130 patients were finally selected. Their average age was 51.91±4.57 years and the average number of visits was 7.51±11.40 times. Patients usually complained two or more addresses, and the most frequent symptoms were hot flushes. 126 patients took herbal medicines and 99 of them took herbal decoctions. 106 patients were treated by acupuncture. 58 patients were treated by pharmacopuncture and Hominis Placenta was used to 50 subjects. As for the improvement rate by symptoms, hot flushes were the highest at 65.5%. We compared the improvement rate of groups taking Guibi-tang-gami A and Guibi-tang-gami B, the common herbal decoction of Daejeon Korean Medicine Hospital of Daejeon University. In the group of Guibi-tang-gami A, the improvement rate of hot flushes was the highest and in the other, vaginal dryness was the highest. Urinary frequency of the group with Hominis Placenta pharmacopuncture showed more than three times higher improvement rate of the non-executive group. Conclusions: We analyzed general characteristics, clinical characteristics, types of Korean medicine treatment, improvement rates by symptoms of 130 outpatients diagnosed with climactic syndrome and postmenopausal syndrome. This study could be used as reference to provide practical data of outpatient treatment for Climacteric Syndrome and Postmenopausal Syndrome.

• Journal of The Korean Society of Inherited Metabolic disease
• /
• v.20 no.2
• /
• pp.37-43
• /
• 2020

Phenylketonuria is the most prevalent disorder caused by an inborn error in aminoacid metabolism. It results from mutations in the phenylalanine hydroxylase (PAH) gene. If untreated or late treated, results in profound and irreversible mental disability. Newborn screening test identify patients with phenylketouria. The early initiation of a phenylalanine restricted diet very soon prevents most of the neuropsychiatric complications. However, the diet therapy is difficult to maintain and compliance is poor, especially in adolescents and adulthood. Since 2015, American Medical College of Medical Genetics and Genomics (ACMG) recommended more strong restrictive diet therapy for target blood level of phenylalanine (<360 umol/L). For over four decades the only treatment was a very restrictive low phenylalanine diet. This changed in 2007 with the approval of cofactor therapy (Tetrahydrobiopterin, BH4) which is effective in up to 30% of patients. Data from controlled clinical trials with sapropterin dihydrochloride indicate a similar occurrence of all-cause adverse events with this treatment and placebo. Large neutral aminoacids (LNAA) competes with phenylalanine for transport across the blood-brain-barrier and have a beneficial effect on executive functioning. A new therapy has just been approved that can be effective in most patients with PAH deficiency regardless of their degree of enzyme deficiency or the severity of their phenotype. Phenylalanine ammonia lyase (PAL-PEG) was approved in the USA by FDA in May of 2018 for adult patients with uncontrolled blood phenylalanine concentrations on current treatment. Nucleic acid therapy (therapeutic mRNA or gene therapy) is likely to provide longer term solutions with few side effects.